hVIVO plc (LON:HVO – Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 28.20 ($0.37) and traded as low as GBX 28 ($0.37). hVIVO shares last traded at GBX 28.50 ($0.38), with a volume of 1,552,155 shares changing hands.
hVIVO Stock Up 1.1 %
The company has a quick ratio of 1.16, a current ratio of 1.48 and a debt-to-equity ratio of 36.50. The company’s fifty day moving average price is GBX 29.08 and its 200-day moving average price is GBX 28.20. The stock has a market capitalization of £196.08 million, a PE ratio of 950.00 and a beta of 0.97.
Insider Buying and Selling at hVIVO
In other news, insider Cathal Friel sold 21,159,176 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of GBX 29 ($0.38), for a total transaction of £6,136,161.04 ($8,105,893.05). 38.31% of the stock is owned by company insiders.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
- Five stocks we like better than hVIVO
- Investing In Preferred Stock vs. Common Stock
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Find and Profitably Trade Stocks at 52-Week Lows
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.